

10/566485

=> d his

(FILE 'HOME' ENTERED AT 08:23:52 ON 27 NOV 2007)

FILE 'CAPLUS' ENTERED AT 08:24:07 ON 27 NOV 2007
E US2006-566485/APPS

L1 1 S E3

FILE 'REGISTRY' ENTERED AT 08:25:13 ON 27 NOV 2007

L2 FILE 'CAPLUS' ENTERED AT 08:25:26 ON 27 NOV 2007
TRA L1 1- RN : 3 TERMS

L3 FILE 'REGISTRY' ENTERED AT 08:25:26 ON 27 NOV 2007
3 SEA L2
E 253-82-7/RN

L4 1 S E3

L5 FILE 'REGISTRY' ENTERED AT 08:30:01 ON 27 NOV 2007
STR 182878-97-3
L6 1 S L5 EXA FUL

L7 FILE 'CAPLUS' ENTERED AT 08:30:30 ON 27 NOV 2007
3 S L6
L8 1 S L7 AND EMOLLIENT
L9 0 S L7 AND PETROLATUM

11/27/2007

10/566485

=> d ibib

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:161002 CAPLUS

DOCUMENT NUMBER: 142:246185

TITLE: Pharmaceutical compositions containing quinazoline derivatives

INVENTOR(S): Kriwet, Katrin

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016322	A2	20050224	WO 2004-EP9273	20040818
WO 2005016322	A3	20051103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004264680	A1	20050224	AU 2004-264680	20040818
CA 2534492	A1	20050224	CA 2004-2534492	20040818
AT 355084	T	20060315	AT 2004-764259	20040818
EP 1675621	A2	20060705	EP 2004-764259	20040818
EP 1675621	B1	20070228		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
CN 1835770	A	20060920	CN 2004-80023530	20040818
BR 2004013545	A	20061017	BR 2004-13545	20040818
JP 2007502799	T	20070215	JP 2006-523603	20040818
ES 2280045	T3	20070901	ES 2004-4764259	20040818
US 2006205746	A1	20060914	US 2006-566485	20060130 <--
IN 2006CN00576	A	20070706	IN 2006-CN576	20060216
MX 2006PA01886	A	20060517	MX 2006-PA1886	20060217
PRIORITY APPLN. INFO.:			GB 2003-19497	A 20030819
			WO 2004-EP9273	W 20040818
OTHER SOURCE(S):	MARPAT 142:246185			


11/27/2007

10/566485

=> d 13 1-

YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2007 ACS on STN
RN 182878-97-3 REGISTRY
ED Entered STN: 07 Nov 1996
CN Quinazoline, 6-[2-(2,5-dimethoxyphenyl)ethyl]-4-ethyl- (CA INDEX NAME)
OTHER NAMES:
CN 6-[2-(2,5-Dimethoxyphenyl)ethyl]-4-ethylquinazoline
MF C20 H22 N2 O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, IMSDRUGNEWS, IMSRESEARCH, PROUSDDR,
SYNTHLINE, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

11/27/2007

=> d l7 ibib abs hitstr

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:161002 CAPLUS

DOCUMENT NUMBER: 142:246185

TITLE: Pharmaceutical compositions containing quinazoline derivatives

INVENTOR(S): Kriwet, Katrin

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016322	A2	20050224	WO 2004-EP9273	20040818
WO 2005016322	A3	20051103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004264680	A1	20050224	AU 2004-264680	20040818
CA 2534492	A1	20050224	CA 2004-2534492	20040818
AT 355084	T	20060315	AT 2004-764259	20040818
EP 1675621	A2	20060705	EP 2004-764259	20040818
EP 1675621	B1	20070228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1835770	A	20060920	CN 2004-80023530	20040818
BR 2004013545	A	20061017	BR 2004-13545	20040818
JP 2007502799	T	20070215	JP 2006-523603	20040818
ES 2280045	T3	20070901	ES 2004-4764259	20040818
US 2006205746	A1	20060914	US 2006-566485	20060130
IN 2006CN00576	A	20070706	IN 2006-CN576	20060216
MX 2006PA01886	A	20060517	MX 2006-PA1886	20060217
PRIORITY APPLN. INFO.:			GB 2003-19497	A 20030819
			WO 2004-EP9273	W 20040818

OTHER SOURCE(S): MARPAT 142:246185


AB Topical pharmaceutical compns., e.g., an emulsion, comprises a quinazoline derivative (a lavendustin analog), and an emollient, and optionally further excipients. Thus, a formulation contained 1% and iso-Pr myristate 10% in addition to other standard excipients.

IT 182878-97-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical compns. containing quinazoline derivs.)

RN 182878-97-3 CAPLUS

CN Quinazoline, 6-[2-(2,5-dimethoxyphenyl)ethyl]-4-ethyl- (CA INDEX NAME)



=> d 17 ibib abs hitstr 2-

YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N)::y

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:662875 CAPLUS

DOCUMENT NUMBER: 139:293651

TITLE: A Practical Synthesis of 6-[2-(2,5-Dimethoxyphenyl)ethyl]-4-ethylquinazoline and the Art of Removing Palladium from the Products of Pd-Catalyzed Reactions

AUTHOR(S): Koenigsberger, Kurt; Chen, Guang-Pei; Wu, Raeann R.; Girgis, Michael J.; Prasad, Kapa; Repic, Oljan; Blacklock, Thomas J.

CORPORATE SOURCE: Process Research and Development, Novartis Institute for Biomedical Research, East Hanover, NJ, 07936, USA

SOURCE: Organic Process Research & Development (2003), 7(5), 733-742

CODEN: OPRDFK; ISSN: 1083-6160

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:293651

AB A concise large-scale synthesis of 1, a new antimitotic agent is described. The key step was a one-pot Sonogashira cross-coupling of an aryl halide with a heteroaryl halide through an acetylene using the readily available 2-methyl-3-butyn-2-ol (7). An innovative approach for palladium removal was designed and successfully scaled-up on a multikilogram scale. The product was crystallized from the crude reaction mixture while keeping the residual palladium in the mother liquor by using Pd-scavenging agents such as N-acetylcysteine or thiourea.


IT 182878-97-3P, 6-[2-(2,5-Dimethoxyphenyl)ethyl]-4-ethylquinazoline

RL: IMF (Industrial manufacture); PUR (Purification or recovery); PREP (Preparation)

(scale-up of and Pd catalyst removal in the synthesis of 6-[2-(2,5-dimethoxyphenyl)ethyl]-4-ethylquinazoline)

RN 182878-97-3 CAPLUS

CN Quinazoline, 6-[2-(2,5-dimethoxyphenyl)ethyl]-4-ethyl- (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:661128 CAPLUS

DOCUMENT NUMBER: 125:301017

TITLE: Preparation of trisubstituted phenyl and quinazoline derivatives for the treatment of inflammatory and proliferative skin diseases and cancer

INVENTOR(S): Nussbaumer, Peter

PATENT ASSIGNEE(S): Sandoz Ltd., Switz.; Sandoz-Patent-Gmbh;
Sandoz-Erfindungen Verwaltungsgesellschaft MbH

SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9628430	A1	19960919	WO 1996-EP1116	19960314
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
CA 2214131	A1	19960919	CA 1996-2214131	19960314
AU 9651443	A	19961002	AU 1996-51443	19960314
AU 704544	B2	19990429		
BR 9607240	A	19971111	BR 1996-7240	19960314
EP 815087	A1	19980107	EP 1996-908043	19960314
EP 815087	B1	20011114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI				
CN 1183774	A	19980603	CN 1996-193716	19960314
CN 1101386	B	20030212		
JP 11503412	T	19990326	JP 1996-527290	19960314
JP 3194963	B2	20010806		
HU 9801828	A2	19990329	HU 1998-1828	19960314
RU 2164224	C2	20010320	RU 1997-117169	19960314
SK 282155	B6	20011106	SK 1997-1245	19960314
AT 208763	T	20011115	AT 1996-908043	19960314
CZ 289944	B6	20020417	CZ 1997-2869	19960314
PT 815087	T	20020429	PT 1996-908043	19960314
ES 2168463	T3	20020616	ES 1996-908043	19960314
PL 185875	B1	20030829	PL 1996-322134	19960314
FI 9703440	A	19971024	FI 1997-3440	19970821
NO 9704118	A	19970908	NO 1997-4118	19970908

10/566485

NO 310356	B1	20010625		
US 5990116	A	19991123	US 1997-913597	19970915
HK 1014440	A1	20030627	HK 1998-112775	19981203
PRIORITY APPLN. INFO.:			GB 1995-5080	A 19950314
			GB 1995-5858	A 19950323
			GB 1995-26593	A 19951228
			WO 1996-EP1116	W 19960314
OTHER SOURCE(S):	MARPAT 125:301017			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention concerns compds. I wherein: R1 and R2 are the same or different and represent OH, alkoxy, acyloxy, alkyl, or acyl, whereby R2 is in the 5- or 6-position, with the proviso that R1 and R2 are not simultaneously OH or acyloxy, and (a) W represents CH₂CH₂, R3 = C(:X)R₆ wherein R₆ = H, alkyl, alkoxy, or amino and X = O, hydroxyimino, or alkoxyimino, R4 = NR₇R₈ wherein R₇ and R₈ are the same or different and represent H, alkyl, acyl, alkoxy, carbonyl, or (b) W = CH₂CH₂, CH:CH, CH₂O, or CH₂NR₅, whereby the heteroatom adheres to ring B and R₅ = H, alkyl, or acyl, R₃ and R₄ form together with ring B a condensed ring system II or III wherein the single/dotted line symbol represents a single or double bond, R₉ = e.g., H, alkylthio, alkyl; Y = N or CR₁₁, R₁₀ = e.g., H, alkyl, acyl; R₁₁ = H, alkoxy, carbonyl, cyano, acyl; Z = O or S; and V = NH if the single/dotted line represents a single bond, and N if the single/dotted line represents a double bond (with provisos), and their use in the prevention or treatment of inflammatory and proliferative skin diseases and cancer. Thus, e.g., hydrogenation of 6-[2-(2,5-dimethoxyphenyl)ethynyl]-4-ethylquinazoline afforded 6-[2-(2,5-dimethoxyphenyl)ethyl]-4-ethylquinazoline (IV); IV and the corresponding 4-MeO and 4-Me compds. exhibited IC₅₀ of about 10 nM for the inhibition of proliferation in the human keratinocyte cell line HaCaT, and between 10 and 200 nM for inhibition of tumor cell proliferation.


IT 182878-97-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of trisubstituted Ph and quinazoline derivs. for the treatment of inflammatory and proliferative skin diseases and cancer)

RN 182878-97-3 CAPLUS

CN Quinazoline, 6-[2-(2,5-dimethoxyphenyl)ethyl]-4-ethyl- (CA INDEX NAME)



11/27/2007

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Tuesday, November 27, 2007

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L6	(4919934.pn.)	2
		((psoriasis and emollient and psoriasis.ti,ab,clm. and emollient.ti,ab,clm.) and	
<input type="checkbox"/>	L5	(@pd<20030819 or @ad<20030819 or @rlad<20030819 or @prad<20030819))	111
		<i>DB=PGPB,USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L4	((psoriasis and emollient) and psoriasis.ti,ab,clm. and emollient.ti,ab,clm.)	100
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L3	(psoriasis and emollient)	2377
		<i>DB=PGPB,USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L2	(5990116.pn.)	1
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L1	("6-[2-(2,5-Dimethoxyphenyl)ethyl]-4-ethylquinazoline" or "6-[2-(2,5-dimethoxyphenyl)ethyl]-4-ethyl-quinazoline" or (182878-97-3))	0

END OF SEARCH HISTORY



My NCBI
Welcome timott

[All Databases](#)

[PubMed](#)

[Nucleotide](#)

[Protein](#)

[Genome](#)

[Structure](#)

[PMC](#)

[PubC](#)

Search for

[Limits](#)

[Preview/Index](#)

[History](#)

[Clipboard](#)

[Details](#)

[About Entrez](#)
[Entrez Help](#)

- Search History will be lost after eight hours of inactivity.
- Search numbers may not be continuous; all searches are represented.
- To save search indefinitely, click query # and select Save in My NCBI.
- To combine searches use #search, e.g., #2 AND #3 or click query # for more options.

PubChem

[Help | FAQ](#)

[Courses](#)

[PubChem
Substance
Structures supplied by
depositors](#)

[PubChem
Compound
Unique structures with
computed properties](#)

[PubChem
BioAssay
Bioactivity assay
results supplied by
depositors](#)

[PubChem
Structure Search](#)

[PubChem FTP](#)

Search	Most Recent Queries	Time	Result
#6	Search 6-[2-(2,5-dimethoxyphenyl)ethyl]-4-ethyl-Quinazoline	08:52:39	1
#2	Search 6-[2-(2,5-Dimethoxyphenyl)ethyl]-4-ethylquinazoline	08:48:09	0
#1	Search lavendustin	08:21:13	10

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

A service of the [U.S. National Library of Medicine](#) [\[?\]](#)
and the [National Institutes of Health](#)
My NCBI
Welcome [timothythomas](#). [\[Sign Out\]](#)

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC
Journals Books

Search **PubMed** for [Preview](#)
[Go](#) [Clear](#)

[About Entrez](#)
[Text Version](#)

[Limits](#) [Preview/Index](#) **[History](#)** [Clipboard](#) [Details](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorials](#)

[New/Noteworthy](#) 

[E-Utilities](#)

- Search History will be lost after eight hours of inactivity.
- Search numbers may not be continuous; all searches are represented.
- To save search indefinitely, click query # and select Save in My NCBI.
- To combine searches use #search, e.g., #2 AND #3 or click query # for more options.

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[Special Queries](#)

[LinkOut](#)

[My NCBI](#)

Search

Most Recent Queries

Time Result

[#7](#) Search **emollient psoriasis**

11:30:36 [133](#)

[Clear History](#)

Related Resources

[Order Documents](#)

[NLM Mobile](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)